基于网络药理学和分子对接探究麻黄加术汤治疗类风湿关节炎的潜在作用机制

doi:10.3976/j.issn.1002-4026.2022.03.003

Abstract

Abstract:

To explore the potential mechanism of Mahuangjiazhu Decoction in the treatment of rheumatoid arthritis using network pharmacology and molecular docking technology. The main active ingredients of Mahuangjiazhu Decoction and their targets were searched and screened. The targets for rheumatoid arthritis disease were obtained by screening using the GeneCards, OMIM, and Drugbank databases. STRING database and Cytoscape software were used to construct protein-protein interaction networks. Metascape database was used to conduct gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses of the target points of Mahuangjiazhu Decoction in the treatment of rheumatoid arthritis. Cytoscape was used to construct a drug components-targets-pathways network. Finally, AutoDock software was used to perform molecular docking of key components and targets. A total of 131 potential active ingredients of Mahuangjiazhu Decoction and 133 key targets for the treatment of rheumatoid arthritis were screened. The main ingredients included quercetin, luteolin, kaempferol, etc. The core targets included IL-6, TNF, TP53, STAT3, etc. GO and KEGG analyses revealed 2 250 biological processes, 89 cell components, and 152 molecular functions. The enrichment pathways mainly involved the AGE-RAGE, IL-17, and TNF signaling pathways. The results of molecular docking showed that phaseol and glycyrrhizin had good binding activity to key targets such as AKT1, PTGS2, MAPK1, and MAPK8. Thus, Mahuangjiazhu Decoction plays a role in the treatment of rheumatoid arthritis through a multi-component, multi-target, and multi-channel action mode, which provides important scientific information for the treatment of rheumatoid arthritis.

Key words: :Mahuangjiazhu Decoction, rheumatoid arthritis, network pharmacology, molecular docking

CLC Number:

R285.5

LI Xiao-li,YING Tian-hao,TANG Yi-di,ZHU Xuan,SUN Meng-meng,YU Tao,ZHAO Jia-ning,ZHANG Lei-ming. Potential mechanism of Mahuangjiazhu Decoction in the treatment of rheumatoid arthritis based on network pharmacology combined with molecular docking technology[J].Shandong Science, 2022, 35(3): 17-26.

Figures/Tables 8

Table 1

Fig.1

Table 2

Fig.2

Fig.3

Fig.4

Table 3

Fig.5

References 39

[1]	LIU W, FAN Y H, TIAN C Y, et al. Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking[J]. Evidence Based Complementary and Alternative Medicine, 2020, 2020: 7151634. DOI: 10.1155/2020/7151634. doi: 10.1155/2020/7151634
[2]	SPARKS J A. Rheumatoid arthritis[J]. Annals of Internal Medicine, 2019, 170(1): ITC1. DOI: 10.7326/aitc201901010. doi: 10.7326/aitc201901010
[3]	RHEUMATOID A. Rheumatoid arthritis[J]. Nature Reviews Disease Primers, 2018, 4: 18002. DOI: 10.1038/nrdp.2018.2. doi: 10.1038/nrdp.2018.2
[4]	FIRESTEIN G S, MCINNES I B. Immunopathogenesis of rheumatoid arthritis[J]. Immunity, 2017, 46(2): 183-196.DOI: 10.1016/j.immuni.2017.02.006. doi: 10.1016/j.immuni.2017.02.006
[5]	ALETAHA D, SMOLEN J S. Diagnosis and management of rheumatoid arthritis: A review[J]. JAMA, 2018, 320(13): 1360-1372. DOI: 10.1001/jama.2018.13103. doi: 10.1001/jama.2018.13103
[6]	van VOLLENHOVEN R. Treat-to-target in rheumatoid arthritis:are we there yet?[J]. Nature Reviews Rheumatology, 2019, 15(3): 180-186. DOI: 10.1038/s41584-019-0170-5. doi: 10.1038/s41584-019-0170-5
[7]	RUTHERFORD A I, PATARATA E, SUBESINGHE S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis[J]. Rheumatology, 2018, 57(6): 997-1001. DOI: 10.1093/rheumatology/key023. doi: 10.1093/rheumatology/key023
[8]	周春瑜, 陈艳林, 付庭娜, 等. 中医辨治类风湿关节炎的研究进展[J]. 风湿病与关节炎, 2020, 9(10): 72-75. DOI: 10.3969/j.issn.2095-4174.2020.10.020. doi: 10.3969/j.issn.2095-4174.2020.10.020
[9]	徐茂林. 经方辨治类风湿性关节炎一得[J]. 国医论坛, 2007(1): 9-10. DOI: 10.3969/j.issn.1002-1078.2007.01.005. doi: 10.3969/j.issn.1002-1078.2007.01.005
[10]	张瑞. 《金匮要略》痹病病因证治探析[J]. 中医研究, 2020, 33(12): 1-3.DOI: 10.3969/j.issn.1001-6910.2020.12.01. doi: 10.3969/j.issn.1001-6910.2020.12.01
[11]	杜以梅. 经方在痹证治疗中的应用研究[D]. 南京: 南京中医药大学, 2007.
[12]	张安东. 麻黄加术汤加味应用于风湿病的临床研究进展[J]. 光明中医, 2019, 34(23):3694-3696. DOI: 10.3969/j.issn.1003-8914.2019.23.065. doi: 10.3969/j.issn.1003-8914.2019.23.065
[13]	邓慧芳. 基于源流梳理及名词考据的仲景微汗法应用阐释与实证研究[D]. 北京: 北京中医药大学, 2018.
[14]	徐琦, 尹抗抗, 谭达全, 等. 麻黄加术汤对大鼠类风湿性关节炎模型作用机制的研究[J]. 湖南中医药大学学报, 2011, 31(5): 13-15. DOI: 10.3969/j.issn.1674-070X.2011.05.004.013.03. doi: 10.3969/j.issn.1674-070X.2011.05.004.013.03
[15]	徐琦, 王红梅, 谭达全. 类风湿性关节炎患者外周血T细胞亚群经麻黄加术汤干预前后变化的研究[J]. 湖南中医杂志, 2014, 30(11): 157-159. DOI: 10.16808/j.cnki.issn1003-7705.2014.11.077. doi: 10.16808/j.cnki.issn1003-7705.2014.11.077
[16]	解静, 高杉, 李琳, 等. 网络药理学在中药领域中的研究进展与应用策略[J]. 中草药, 2019, 50(10): 2257-2265. DOI: 10.7501/j.issn.0253-2670.2019.10.001. doi: 10.7501/j.issn.0253-2670.2019.10.001
[17]	SHI X Q, YUE S J, TANG Y P, et al. A network pharmacology approach to investigate the blood enriching mechanism of Danggui buxue Decoction[J]. Journal of Ethnopharmacology, 2019, 235: 227-242. DOI: 10.1016/j.jep.2019.01.027. doi: 10.1016/j.jep.2019.01.027
[18]	HSIN K Y, GHOSH S, KITANO H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One. 2013, 8(12): e83922. DOI: 10.1371/journal.pone.0083922. doi: 10.1371/journal.pone.0083922
[19]	葛高月, 郑新春. 类风湿关节炎中西医治疗进展[J]. 辽宁中医药大学学报, 2021, 23(2): 84-89. DOI: 10.13194/j.issn.1673-842x.2021.02.019. doi: 10.13194/j.issn.1673-842x.2021.02.019
[20]	黄裕成. 麻黄加术汤治疗类风湿性关节炎的临床观察[J]. 光明中医, 2018, 33(5): 676-678. DOI: 10.3969/j.issn.1003-8914.2018.05.035. doi: 10.3969/j.issn.1003-8914.2018.05.035
[21]	魏斐菲. 麻黄加术汤加味疗法治疗风湿病临床研究[J]. 亚太传统医药, 2017, 13(6):144-145. DOI: 10.11954/ytctyy.201706063. doi: 10.11954/ytctyy.201706063
[22]	XUE H M, TU Y H, MA T, et al. Lactoferrin inhibits IL-1β-induced chondrocyte apoptosis through AKT1-induced CREB1 activation[J]. Cellular Physiology and Biochemistry, 2015, 36(6): 2456-2465. DOI: 10.1159/000430206. doi: 10.1159/000430206
[23]	ZHAO X Y, WANG T J, CAI B, et al. MicroRNA-495 enhances chondrocyte apoptosis, senescence and promotes the progression of osteoarthritis by targeting AKT1[J]. American Journal of Translational Research, 2019, 11(4): 2232-2244.
[24]	MIYASHITA T, KAWAKAMI A, MAMI T M, et al. Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells[J]. Biochemical and Biophysical Research Communications, 2003, 312(2): 397-404.DOI: 10.1016/j.bbrc.2003.10.141. doi: 10.1016/j.bbrc.2003.10.141
[25]	LIU H T, POPE R M. The role of apoptosis in rheumatoid arthritis[J]. Current Opinion in Pharmacology, 2003, 3(3): 317-322. DOI: 10.1016/S1471-4892(03)00037-7. doi: 10.1016/S1471-4892(03)00037-7
[26]	DAI Q D, ZHOU D, XU L P, et al. Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats[J]. Drug Design, Development and Therapy, 2018, 12: 4095-4105. DOI: 10.2147/DDDT.S175763. doi: 10.2147/DDDT.S175763
[27]	YE Y, BAO C D, FAN W. Overexpression of miR-101 may target DUSP₁ to promote the cartilage degradation in rheumatoid arthritis[J]. Journal of Computational Biology, 2019, 26(10): 1067-1079. DOI: 10.1089/cmb.2019.0021. doi: 10.1089/cmb.2019.0021
[28]	范星宇, 洪梦琴, 杨敏. IL-6与类风湿关节炎的关系及作用机制的研究进展[J]. 世界最新医学信息文摘, 2019, 19(86): 65. DOI: 10.19613/j.cnki.1671-3141.2019.86.026. doi: 10.19613/j.cnki.1671-3141.2019.86.026
[29]	REDLICH K, SMOLEN J S. Inflammatory bone loss: Pathogenesis and therapeutic intervention[J]. Nature Reviews Drug Discovery, 2012, 11(3): 234-250. DOI: 10.1038/nrd3669. doi: 10.1038/nrd3669
[30]	WANG M L, LI H Y, WANG Y F, et al. Anti-rheumatic properties ofgentiopicroside are associated with suppression of ROS-NF-κB-NLRP3 axis in fibroblast-like synoviocytes and NF-κB pathway in adjuvant-induced arthritis[J]. Frontiers in Pharmacology, 2020, 11: 515. DOI: 10.3389/fphar.2020.00515. doi: 10.3389/fphar.2020.00515
[31]	CHOW Y Y, CHIN K Y. The role of inflammation in the pathogenesis of osteoarthritis[J]. Mediators of Inflammation, 2020, 2020: 8293921. DOI: 10.1155/2020/8293921. doi: 10.1155/2020/8293921
[32]	CHENG B C Y, FU X Q, GUO H, et al. The genus Rosa and arthritis: overview on pharmacological perspectives[J]. Pharmacological Research, 2016, 114: 219-234. DOI: 10.1016/j.phrs.2016.10.029. doi: 10.1016/j.phrs.2016.10.029
[33]	MILLERAND M, BERENBAUM F, JACQUES C. Danger signals andinflammaging in osteoarthritis[J]. Clinical and Experimental Rheumatology, 2019, 37(5): 48-56.
[34]	BONAVENTURA P, LAMBOUX A, ALBARÈDE F, et al. Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation[J]. PLoS One, 2018, 13(5): e0196285. DOI: 10.1371/journal.pone.0196285. doi: 10.1371/journal.pone.0196285
[35]	HU X M, TANG J H, ZENG G, et al. RGS1 silencing inhibits the inflammatory response and angiogenesis in rheumatoid arthritis rats through the inactivation of Toll-like receptor signaling pathway[J]. Journal of Cellular Physiology, 2019, 234(11): 20432-20442. DOI: 10.1002/jcp.28645. doi: 10.1002/jcp.28645
[36]	ARLEEVSKAYA M I, LARIONOVA R V, BROOKS W H, et al. Toll-like receptors, infections, and rheumatoid arthritis[J]. Clinical Reviews in Allergy & Immunology, 2020, 58(2): 172-181. DOI: 10.1007/s12016-019-08742-z. doi: 10.1007/s12016-019-08742-z
[37]	YUAN K, ZHU Q Q, LU Q Y, et al. Quercetin alleviates rheumatoid arthritis by inhibiting neutrophil inflammatory activities[J]. The Journal of Nutritional Biochemistry, 2020, 84: 108454. DOI: 10.1016/j.jnutbio.2020.108454. doi: 10.1016/j.jnutbio.2020.108454
[38]	HOU Y N, WU J C, HUANG Q, et al. Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts[J]. Cell Biology International, 2009, 33(2): 135-147.DOI: 10.1016/j.cellbi.2008.10.005. doi: 10.1016/j.cellbi.2008.10.005
[39]	PAN D M, LI N, LIU Y Y, et al. Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway[J]. International Immunopharmacology, 2018, 55: 174-182. DOI: 10.1016/j.intimp.2017.12.011. doi: 10.1016/j.intimp.2017.12.011

编号		活性成分	来源
MOL002311		Glycyrol(甘草酚)	甘草、杏仁
MOL012922		l-SPD(左旋千金藤啶碱)	杏仁
MOL004990		7,2',4'-trihydroxy-5-methoxy-3-arylcoumarin(7,2',4'-三羟基-5-甲氧基-3-苯基香豆素)	甘草
MOL004904		Licopyranocoumarin(甘草吡喃香豆素)	甘草
MOL004891		Shinpterocarpin	甘草
MOL007207		Machiline(乌药碱)	杏仁
MOL005017		Phaseol	甘草、杏仁
MOL004841	Licochalcone B(甘草查尔酮B)			甘草、杏仁
MOL004810	glyasperin F(粗毛甘草素F)			甘草
MOL001484	Inermine(高丽槐素)			甘草
MOL000500	Vestitol(维斯体素)			甘草
MOL005007	Glyasperins M(粗毛甘草素M)			甘草
MOL005190	Eriodictyol(圣草酚)			麻黄
MOL004941	(2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one			甘草
MOL004959	1-Methoxyphaseollidin(1-甲氧基菜豆素)			甘草
MOL000392	Formononetin(刺芒柄花素)			甘草
MOL003410	Ziziphin_qt			杏仁
MOL004863	3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromone			甘草
MOL004903	Liquiritin(甘草苷)			甘草、杏仁
MOL004808	glyasperin B(粗毛甘草素B)			甘草

靶点	靶点名称	度值	靶点	靶点名称	度值
IL-6	白介素6	65	MMP9	基质金属蛋白酶-9	42
TNF	肿瘤坏死因子	58	EGF	促表皮生长因子	41
TP53	细胞肿瘤抗原 p53	55	EGFR	表皮生长因子受体	40
STAT3	信号转导和转录激活因子3	55	PTGS2	前列腺素内过氧化物合酶 2	40
AKT1	蛋白激酶B	54	CCL2	C-C趋化因子 2	39
VEGFA	血管内皮生长因子 A	53	RELA	转录因子p65	39
CXCL8	白介素8	50	APP	淀粉样前体蛋白	37
JUN	c-Jun氨基末端激酶	50	ICAM1	胞间黏附分子 1	37
MAPK8	丝裂原活化蛋白激酶 8	49	MYC	Myc原癌基因蛋白	36
MAPK1	丝裂原活化蛋白激酶 1	48	IL-10	白介素10	36
IL-1β	白介素1-β	47	SRC	类固醇受体共激活因子	35

活性成分	结合自由能/(kJ·mol^-1)
活性成分	AKT1	PTGS2	MAPK1	MAPK8	RELA	STAT3	CXCL8	IL1B	IL6	TNF
槲皮素	-9.5	-9.6	-8.4	-7.6	-7.3	-7.3	-6.6	-7.0	-7.1	-6.7
木犀草素	-9.5	-9.4	-8.4	-8.1	-6.9	-7.8	-6.5	-6.8	-7.0	-6.2
山奈酚	-9.5	-9.7	-8.2	-7.5	-7.3	-7.0	-6.7	-6.7	-6.7	-6.3
柚皮素	-9.6	-9.1	-7.9	-7.6	-7.0	-7.7	-6.3	-6.9	-6.8	-6.4
刺芒柄花素	-9.7	-9.1	-7.9	-7.5	-7.1	-6.9	-6.8	-6.4	-6.3	-5.8
甘草酚	-10.6	-10.3	-9.3	-8.9	-7.1	-7.7	-6.8	-7.2	-6.6	-6.9
花旗松素	-9.6	-9.4	-8.1	-7.8	-7.0	-7.4	-6.6	-7.1	-6.7	-6.5
(+)-儿茶素	-9.9	-9.2	-8.5	-8.8	-7.5	-7.4	-7.2	-7.7	-7.3	-7.3
甘草查尔酮 B	-9.5	-8.5	-7.4	-7.2	-6.6	-6.6	-6.0	-6.4	-6.2	-5.8
Phaseol	-11.2	-10.2	-9.4	-9.0	-7.7	-8.1	-7.0	-7.3	-7.7	-7.3
光甘草定	-9.7	-8.4	-8.0	-8.8	-8.6	-7.7	-6.8	-7.5	-7.3	-6.4
β-谷甾醇	-10.8	-8.3	-9.1	-8.7	-6.9	-7.9	-6.9	-7.7	-7.3	-7.0

Potential mechanism of Mahuangjiazhu Decoction in the treatment of rheumatoid arthritis based on network pharmacology combined with molecular docking technology

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 39

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIU Kechun, WANG Yongcheng, ZANG Xiaohan, XIA Qing, ZHANG Yun, ZHANG Shanshan, SUN Chen. Advancements in network pharmacology and zebrafish modeling for studying traditional Chinese medicine’s effective substances and mechanisms of action [J]. Shandong Science, 2024, 37(2): 29-35.
[2]	FU Zhaoju, CHENG Guo, LIN Dengmei, LI Jun, ZHANG Nannan. Experimental study and network pharmacological analysis of the anti-inflammatory action mechanism of Mahonia bealei (Fort.) Carr. [J]. Shandong Science, 2024, 37(1): 24-31.
[3]	CHEN Chun, QI Daqing, PAN Jingwen. Clinical significance of stromal cell score in gastric cancer and intervention with Weifuchun capsules [J]. Shandong Science, 2023, 36(6): 38-47.
[4]	MU Nana, LIAO Binbin, LI Zhen, LI Jipin, LI Yihua, WANG Ying, CHEN Xubing. Investigating the mechanism of action of Elephantopus scaber L. in the treatment of ulcerative colitis based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(6): 48-55.
[5]	WANG Yifan, ZHANG Zhe, TIAN Caijun. Mechanism of Sanhuang Xiexin decoction in treatment of Alzheimer's disease based on network pharmacology and molecular docking method [J]. Shandong Science, 2023, 36(5): 19-26.
[6]	FU Mengya, AO Huihao, BU Chao, PENG Tangyi, WU Deling, HAN Yanquan, HONG Yan. Forecast analysis of the quality markers of Zingiberis Rhizoma based on fingerprints and network pharmacology [J]. Shandong Science, 2023, 36(4): 35-41.
[7]	YIN Zhipeng, GAO Yunyun, LIU Wenwen, GUO Pengbo, ZHAO Yinghui. Exploring the mechanism of Xiangsha Liujunzi Decoction in treating Helicobacter pylori-associated gastritis based on network pharmacology and molecular docking technology [J]. Shandong Science, 2023, 36(4): 52-60.
[8]	SUN Tiefeng, DONG Limin, JIAO Ziqi, WANG Ping. Exploration of the dosing pattern and anti-respiratory syncytial virus mechanism of traditional Chinese medicine based on data mining and network pharmacology [J]. Shandong Science, 2023, 36(3): 1-9.
[9]	ZHU Jie, WANG Zheng, LIANG Yanni. The mechanism of Xiaoqinglong Decoction in treatment of COVID-19 based on network pharmacology [J]. Shandong Science, 2023, 36(3): 10-17.
[10]	DONG Pengjun, CAI Bin. Action mechanism of the herb pair Aurantii Fructus Immaturus-Magnoliae Officinalis Cortex in the treatment of slow transit constipation based on network pharmacology and metabolomics [J]. Shandong Science, 2023, 36(3): 18-26.
[11]	ZHAO Xin, HUANG Biyun, WU Dan, ZHANG Mei. The mechanism of Guishaozhenxian Tablet in the treatment of temporal lobe epilepsy based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(3): 27-37.
[12]	WANG Yifan, ZHANG Yanyan, TIAN Caijun. Network pharmacology to explore the mechanism of Wangbi formula in the treatment of rheumatoid arthritis [J]. Shandong Science, 2023, 36(3): 38-45.
[13]	LIU Wenwen, GAO Yunyun, YIN Zhipeng, LÜ Gang, WANG Yu, ZHAO Yinghui. Network pharmacology and molecular docking analysis of the mechanism of Huanglian Wendan Decoction in the treatment of Helicobacter pylori associated gastritis [J]. Shandong Science, 2023, 36(2): 23-32.
[14]	LIU Wenwen, LI Changgeng, KONG Na, LIU Shuang, DONG Hongjing. Study on the mechanism of Shiweiyipi Granules based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(2): 33-40.
[15]	SHEN Fengxia, FAN Jianwei, LI Qian, MA Yun, FENG Qun, GUAN Yongxia. Analysis of the mechanism of Yinzhihuang Granules in liver fibrosis treatment based on network pharmacology and molecular docking [J]. Shandong Science, 2023, 36(1): 23-33.